Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key “don’t eat me” signals found in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in models of glioblastoma, highlighting a promising strategy.
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.
